Healthcare / BiotechnologyNasdaqCM
$5.85
+0.08 (+1.39%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-48.0M · quality 50.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$19M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-242.7%
↓Gross Margin
N/A
•Debt/Equity
1.28
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.69x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-45.5M · FCF $-31.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Net Income | $-45.5M | $-45.5M | $-64.8M | $-102.1M | $-136.1M | $-185.4M | $-112.2M | $-45.6M |
| EBITDA | $-42.4M | $-42.4M | $-62.1M | $-99.3M | $-131.7M | $-184.2M | $-112.1M | $-37.1M |
| EPS | -14.35 | -14.35 | -21.40 | -37.20 | -50.00 | -69.60 | -58.20 | — |
| Balance Sheet | ||||||||
| Debt/Equity | 1.28 | 1.28 | 0.42 | 0.24 | 0.13 | — | — | — |
| Current Ratio | 1.73 | 1.73 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-31.5M | $-31.5M | $-48.0M | $-78.4M | $-123.5M | — | — | — |
| Returns | ||||||||
| ROE | -242.7% | -242.7% | -105.7% | -91.7% | -67.6% | -58.2% | -36.8% | 81.1% |
| Valuation | ||||||||
| P/B | 0.99 | 0.99 | 0.82 | 0.46 | 0.51 | — | — | — |
| Growth & Yield | ||||||||
| EPS Growth | 32.9% | 32.9% | 42.5% | 25.6% | — | -19.6% | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-32.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-21.40 → -14.35
Residual
-32.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.